Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

July 25, 2024

Study Completion Date

July 25, 2024

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Psilocybin (0.25mg/kg)

Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.

DRUG

Niacin (250mg)

A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.

Trial Locations (1)

06519

Connecticut Mental Health Center, New Haven

Sponsors
All Listed Sponsors
collaborator

Heffter Research Institute

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Yale University

OTHER